These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Mood, cognition and serotonin transporter availability in current and former ecstasy (MDMA) users: the longitudinal perspective. Thomasius R; Zapletalova P; Petersen K; Buchert R; Andresen B; Wartberg L; Nebeling B; Schmoldt A J Psychopharmacol; 2006 Mar; 20(2):211-25. PubMed ID: 16510479 [TBL] [Abstract][Full Text] [Related]
6. Ecstasy intoxication: an overlap between serotonin syndrome and neuroleptic malignant syndrome. Demirkiran M; Jankovic J; Dean JM Clin Neuropharmacol; 1996 Apr; 19(2):157-64. PubMed ID: 8777769 [TBL] [Abstract][Full Text] [Related]
7. MDMA (3,4-methylenedioxymethamphetamine) or ecstasy: the contemporary human and animal research perspective. Parrott AC; Marsden CA J Psychopharmacol; 2006 Mar; 20(2):143-6. PubMed ID: 16510473 [No Abstract] [Full Text] [Related]
8. [3,4-methylenedioxymethamphetamine ('ecstasy'): its long-term emotional and cognitive effects, and serotonin depletion]. Molero-Chamizo A Rev Neurol; 2005 Jul 16-31; 41(2):108-14. PubMed ID: 16028190 [TBL] [Abstract][Full Text] [Related]
9. The confounding problem of polydrug use in recreational ecstasy/MDMA users: a brief overview. Gouzoulis-Mayfrank E; Daumann J J Psychopharmacol; 2006 Mar; 20(2):188-93. PubMed ID: 16510477 [TBL] [Abstract][Full Text] [Related]
11. Increased effects of 3,4-methylenedioxymethamphetamine (ecstasy) in a rat model of depression. Jaehne EJ; Majumder I; Salem A; Irvine RJ Addict Biol; 2011 Jan; 16(1):7-19. PubMed ID: 20192951 [TBL] [Abstract][Full Text] [Related]
15. [Two cases of "Ecstasy (MDMA)" poisoning]. Chishiro T; Matsubara M; Kiuchi S Chudoku Kenkyu; 2003 Oct; 16(4):463-4. PubMed ID: 14740570 [No Abstract] [Full Text] [Related]
16. Neuroimaging findings with MDMA/ecstasy: technical aspects, conceptual issues and future prospects. Reneman L; de Win MM; van den Brink W; Booij J; den Heeten GJ J Psychopharmacol; 2006 Mar; 20(2):164-75. PubMed ID: 16510475 [TBL] [Abstract][Full Text] [Related]
17. MDMA in humans: factors which affect the neuropsychobiological profiles of recreational ecstasy users, the integrative role of bioenergetic stress. Parrott AC J Psychopharmacol; 2006 Mar; 20(2):147-63. PubMed ID: 16510474 [TBL] [Abstract][Full Text] [Related]
18. Toxicity of drug abuse--amphetamine designer drugs (ecstasy): mental effects and consequences of single dose use. Mørland J Toxicol Lett; 2000 Mar; 112-113():147-52. PubMed ID: 10720724 [TBL] [Abstract][Full Text] [Related]
19. Ecstasy--deadly risk even outside rave parties. Libiseller K; Pavlic M; Grubwieser P; Rabl W Forensic Sci Int; 2005 Oct; 153(2-3):227-30. PubMed ID: 16139114 [TBL] [Abstract][Full Text] [Related]
20. In vivo imaging of cerebral serotonin transporter and serotonin(2A) receptor binding in 3,4-methylenedioxymethamphetamine (MDMA or "ecstasy") and hallucinogen users. Erritzoe D; Frokjaer VG; Holst KK; Christoffersen M; Johansen SS; Svarer C; Madsen J; Rasmussen PM; Ramsøy T; Jernigan TL; Knudsen GM Arch Gen Psychiatry; 2011 Jun; 68(6):562-76. PubMed ID: 21646575 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]